Abstract: A pharmaceutical preparation characterized by combination of (A) and (B) is useful for the prevention and treatment of a disease related to anti-obesity effect, wherein (A) is a compound represented by formula: or a pharmaceutically acceptable salt thereof, and (B) is at least one agent selected from the group consisting of agents having anti-obesity action, agents for controlling blood glucose level, agents for controlling cholesterol and/or triglyceride in blood, and agents for controlling blood pressure.

Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.

Abstract: The present invention provides a preparation that is minimally colored through irradiation with light by coating a preparation containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a crystal thereof with a light stabilizing substance and a polymer, particularly with one or more of titanium oxide and talc used as the light stabilizing substance and hypromellose used as the polymer.

Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.

Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.

Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like; y is 0 or 1; R1 is hydrogen or the like; R2a and R2b are taken together with an adjacent carbon atom to form ring B; ring B is a substituted or unsubstituted non-aromatic carbocycle or the like; R3a is hydrogen or the like; R3b is hydrogen or the like; R4a is represented by formula: L1 is a single bond or the like; L2 is —C(?O)— or the like; La is a single bond or the like; R7 is substituted or unsubstituted alkyl or the like; R4b is substituted or unsubstituted alkyl or the like; R4c is each independently halogen or the like.

Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.

Abstract: The present invention provides a preparation that is minimally colored through irradiation with light by coating a preparation containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a crystal thereof with a light stabilizing substance and a polymer, particularly with one or more of titanium oxide and talc used as the light stabilizing substance and hypromellose used as the polymer.

Abstract: The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance.

Abstract: The present invention relates to a compound that has GLP-1 receptor agonist activity and is useful as a therapeutic or prophylactic agent for diseases associated with the GLP-1 receptor, or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition containing the compound or its pharmaceutically acceptable salt. Provided is a compound represented by formula (I): wherein A1 is C(R5) or the like, A2 is C(R6) or the like, A3 is C(R7) or the like, R5, R6, and R7 are each independently a hydrogen atom or the like, R1 is carboxy or the like, R2 is substituted or unsubstituted alkyl or the like, —X— is —O— or the like, the ring represented by: is a ring represented by: ?and the like wherein R10 is each independently halogen or the like, s is 0 or the like, R13 is each independently a hydrogen atom or the like, and R3 is substituted or unsubstituted aromatic carbocyclyl or the like, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: is or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

Abstract: The chimeric antigen receptor that recognizes CCR8 as an antigen of the present invention has cytotoxic activity against CCR8-expressing cells by being expressed in effector cells.

Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.

Abstract: The present invention provides novel cationic lipids having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by Formula (I) or a pharmacologically acceptable salt thereof. In the Formula (I), R1 is a substituted or unsubstituted formula: (CH2)a—L1—(CH2)b—CH3; R2 is a substituted or unsubstituted C5-C20 alkyl group or a substituted or unsubstituted formula: —(CH2)c—L2—(CH2)a—CH3; L1 and L2 are each independently —C(?O)O—, —OC(?O)—, or —OC(?O)O—; a, b, c, and d are each independently an integer of at least 1, and the total of a and b and the total of c and d are each an integer of 5 to 25; R3 to R7 are each independently a hydrogen atom, a substituted or unsubstituted C1-C6 alkyl group, or the like; R8, R9, and R10 are each a hydrogen atom; the constituent atoms in the Formula (I) may form a ring; Z is —OC(?O)—, —C(?O)O—, —OC(?O)O—, or the like; and X is O or S.

Abstract: The present invention provides a method for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity, and a kit for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity.

Abstract: The present invention provides a formulation for oral administration, comprising a triazine derivative having virus proliferation inhibitory action.

Abstract: A condensed heterocyclic compound has a sepiapterin reductase inhibitory action and is particularly useful for treatment of a pain. The condensed heterocyclic compound represented by Formula (I) below (R1 represents a hydrocarbon group or the like; R2 and R3 represent a hydrogen atom or the like; R4, X, and Y represent defined substituents), a tautomer or a pharmaceutically acceptable salt of the compound, or a solvate of any of these.

Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.

Abstract: Provided are a compound having serotonin 5-HT2A receptor antagonism and/or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and/or inverse agonism comprising them.

Abstract: The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance.